≥95%(HPLC) , 439083-90-6

Synonym(s):
2-(3,4-Dimethoxybenzyl)-7-{(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl}-5-methyllimidazo[5,1-f][1,2,4]triazin-4(3H)-one;BAY-60−7550;BAY60-7550

CAS NO.：439083-90-6

Empirical Formula: C27H32N4O4

Molecular Weight: 476.57

MDL number: MFCD08702694

PRODUCT Properties

• Boiling point: 680.7±65.0 °C(Predicted)
• Density: 1.24±0.1 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: DMSO:21.65(Max Conc. mg/mL);45.43(Max Conc. mM); Ethanol:10.0(Max Conc. mg/mL);20.98(Max Conc. mM)
• pka: 14.54±0.20(Predicted)
• form: powder
• color: white to light brown

Description and Uses

The second messengers cAMP and cGMP are important mediators of signal transduction and hence a wide range of cellular processes including vasodilation and synaptic plasticity. Type 2 cyclic nucleotide phosphodiesterases (PDE2) isoforms inactivate cAMP and cGMP by hydrolyzing the phosphodiester bond. BAY 60-7550 is a potent PDE2 inhibitor with IC₅₀ values of 2.0 nM (bovine) and 4.7 nM (human). It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A. At 3 mg/kg BAY 60-7550 antagonizes oxidative stress-induced anxiety-like behavioral effects in mice by increasing cGMP signaling. At 1 mg/kg BAY 60-7550 improves the performance of rats in an object location task, enhancing cAMP/cGMP-mediated object and spatial memory consolidation.

The compound induced anxiety by inhibition of Phosphodiesterase-2 (PDE2), which regulates cGMP and cAMP signaling